Lanterne Dx completed its merger with BroadOak portfolio company Flagship Biosciences.
OCT 5, 2026
A discovery and clinical-phase histopathology CRO serving pharmaceutical and biotechnology companies with biomarker discovery, development, validation, pathology, digital image analysis, and clinical trial support
A discovery and clinical-phase histopathology CRO serving pharmaceutical and biotechnology companies with biomarker discovery, development, validation, pathology, digital image analysis, and clinical trial support. Its CAP/CLIA-accredited laboratory supports precision oncology programs from preclinical research through clinical development.